Bionoxx Inc.
Tuesday, June 04, 2024
Oncology
Company Presentation Theater 1
Bionoxx Inc. (Bionoxx), founded in 2016, is committed to demystifying the functional heterogeneity of circulating neutrophils in cancer as well as immune-related diseases.
Based on BNX-IFS (Immune Function States), a unique assay that detects activated neutrophils implicated in impaired immune homeostasis, we have shown effective immunomodulatory strategies in the treatment of ICI-resistant tumor mice model and viral sepsis mice model.
Employing this strategy, Bionoxx obtained USFDA acceptance to proceed with a first-in-human trial with Immuno-Oncology (IO) virotherapy (mOTS-400) aimed at overcoming ICI resistance.
BNX-IFS's ability to detect specific immune states in circulating blood is essential for tailoring immunomodulatory strategies across immune-related conditions. BNX is actively seeking partnerships with leading pharmaceutical companies to further our mission and make significant strides in the field of immunotherapy.
Company Website:
http://www.bionoxx.com
Lead Product in Development:
immuno-oncology therapy
Company HQ City
Seongnam
Company HQ State
Gyeonggi-do
Company HQ Country
Korea, Republic of
CEO/Top Company Official
Soobeum Yi
Development Phase of Primary Product
Phase I
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())